241 related articles for article (PubMed ID: 18285836)
1. Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach.
Tischkowitz M; Hamel N; Carvalho MA; Birrane G; Soni A; van Beers EH; Joosse SA; Wong N; Novak D; Quenneville LA; Grist SA; ; Nederlof PM; Goldgar DE; Tavtigian SV; Monteiro AN; Ladias JA; Foulkes WD
Eur J Hum Genet; 2008 Jul; 16(7):820-32. PubMed ID: 18285836
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for cell cycle checkpoint control by the BRCA1-CtIP complex.
Varma AK; Brown RS; Birrane G; Ladias JA
Biochemistry; 2005 Aug; 44(33):10941-6. PubMed ID: 16101277
[TBL] [Abstract][Full Text] [Related]
3. Phosphopeptide binding specificities of BRCA1 COOH-terminal (BRCT) domains.
Rodriguez M; Yu X; Chen J; Songyang Z
J Biol Chem; 2003 Dec; 278(52):52914-8. PubMed ID: 14578343
[TBL] [Abstract][Full Text] [Related]
4. Structural basis of BACH1 phosphopeptide recognition by BRCA1 tandem BRCT domains.
Botuyan MV; Nominé Y; Yu X; Juranic N; Macura S; Chen J; Mer G
Structure; 2004 Jul; 12(7):1137-46. PubMed ID: 15242590
[TBL] [Abstract][Full Text] [Related]
5. Combining Homologous Recombination and Phosphopeptide-binding Data to Predict the Impact of
Petitalot A; Dardillac E; Jacquet E; Nhiri N; Guirouilh-Barbat J; Julien P; Bouazzaoui I; Bonte D; Feunteun J; Schnell JA; Lafitte P; Aude JC; Noguès C; Rouleau E; Lidereau R; Lopez BS; Zinn-Justin S; Caputo SM;
Mol Cancer Res; 2019 Jan; 17(1):54-69. PubMed ID: 30257991
[No Abstract] [Full Text] [Related]
6. Structure of the BRCT repeats of BRCA1 bound to a BACH1 phosphopeptide: implications for signaling.
Shiozaki EN; Gu L; Yan N; Shi Y
Mol Cell; 2004 May; 14(3):405-12. PubMed ID: 15125843
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.
Lee MS; Green R; Marsillac SM; Coquelle N; Williams RS; Yeung T; Foo D; Hau DD; Hui B; Monteiro AN; Glover JN
Cancer Res; 2010 Jun; 70(12):4880-90. PubMed ID: 20516115
[TBL] [Abstract][Full Text] [Related]
8. BRCT domains: phosphopeptide binding and signaling modules.
Rodriguez MC; Songyang Z
Front Biosci; 2008 May; 13():5905-15. PubMed ID: 18508631
[TBL] [Abstract][Full Text] [Related]
9. Characterization of cancer-linked BRCA1-BRCT missense variants and their interaction with phosphoprotein targets.
Drikos I; Nounesis G; Vorgias CE
Proteins; 2009 Nov; 77(2):464-76. PubMed ID: 19452558
[TBL] [Abstract][Full Text] [Related]
10. Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1.
Williams RS; Lee MS; Hau DD; Glover JN
Nat Struct Mol Biol; 2004 Jun; 11(6):519-25. PubMed ID: 15133503
[TBL] [Abstract][Full Text] [Related]
11. Cell signaling. The BRCT domain: signaling with friends?
Caldecott KW
Science; 2003 Oct; 302(5645):579-80. PubMed ID: 14576410
[No Abstract] [Full Text] [Related]
12. Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer.
Clapperton JA; Manke IA; Lowery DM; Ho T; Haire LF; Yaffe MB; Smerdon SJ
Nat Struct Mol Biol; 2004 Jun; 11(6):512-8. PubMed ID: 15133502
[TBL] [Abstract][Full Text] [Related]
13. BRCT repeats as phosphopeptide-binding modules involved in protein targeting.
Manke IA; Lowery DM; Nguyen A; Yaffe MB
Science; 2003 Oct; 302(5645):636-9. PubMed ID: 14576432
[TBL] [Abstract][Full Text] [Related]
14. Structural basis for the BRCA1 BRCT interaction with the proteins ATRIP and BAAT1.
Liu X; Ladias JA
Biochemistry; 2013 Oct; 52(43):7618-27. PubMed ID: 24073851
[TBL] [Abstract][Full Text] [Related]
15. Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation.
Fernandes VC; Golubeva VA; Di Pietro G; Shields C; Amankwah K; Nepomuceno TC; de Gregoriis G; Abreu RBV; Harro C; Gomes TT; Silva RF; Suarez-Kurtz G; Couch FJ; Iversen ES; Monteiro ANA; Carvalho MA
J Biol Chem; 2019 Apr; 294(15):5980-5992. PubMed ID: 30765603
[TBL] [Abstract][Full Text] [Related]
16. Impact of BRCA1 BRCT domain missense substitutions on phosphopeptide recognition.
Coquelle N; Green R; Glover JN
Biochemistry; 2011 May; 50(21):4579-89. PubMed ID: 21473589
[TBL] [Abstract][Full Text] [Related]
17.
Drikos I; Boutou E; Kastritis PL; Vorgias CE
Anticancer Res; 2021 Jun; 41(6):2953-2962. PubMed ID: 34083286
[TBL] [Abstract][Full Text] [Related]
18. Detection of a novel mutation in exon 20 of the BRCA1 gene.
Chakraborty A; Katarkar A; Chaudhuri K; Mukhopadhyay A; Basak J
Cell Mol Biol Lett; 2013 Dec; 18(4):631-8. PubMed ID: 24297685
[TBL] [Abstract][Full Text] [Related]
19. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M
Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317
[TBL] [Abstract][Full Text] [Related]
20. Mutations in the BRCT binding site of BRCA1 result in hyper-recombination.
Dever SM; Golding SE; Rosenberg E; Adams BR; Idowu MO; Quillin JM; Valerie N; Xu B; Povirk LF; Valerie K
Aging (Albany NY); 2011 May; 3(5):515-32. PubMed ID: 21666281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
